PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

S. Branchoux, S. Négrier, Christian de Peretti (), B. Malcolm, J. May, L. Marié, A.F. Gaudin, S. Klijn and T.J. Ignacio
Additional contact information
S. Branchoux: Bristol-Myers Squibb [Rueil-Malmaison]
S. Négrier: Department of Medical Oncology [Lyon] - Centre Léon Bérard [Lyon], UCBL - Université Claude Bernard Lyon 1 - Université de Lyon
Christian de Peretti: ECL - École Centrale de Lyon - Université de Lyon, LSAF - Laboratoire de Sciences Actuarielle et Financière - UCBL - Université Claude Bernard Lyon 1 - Université de Lyon
J. May: BNITM - Bernhard Nocht Institute for Tropical Medicine - Bernhard-Nocht-Institut für Tropenmedizin [Hamburg, Germany]

Post-Print from HAL

Abstract: Objectives Nivolumab in combination with ipilimumab (NIVO+IPI) is the first immuno-oncology combination to demonstrate significant, long-term overall survival (OS) benefit in previously untreated patients with intermediate- to poor-risk advanced renal cell carcinoma (1L RCC) compared with standard of care (sunitinib). The objective of this study was to assess the cost-effectiveness of NIVO+IPI compared with sunitinib in 1L RCC from the French all payers perspective. Methods A three-state partitioned survival model (progression-free disease, progressed disease and death) was developed with a one-week cycle length and lifetime time horizon. The model used patient characteristics, progression-free survival, OS, safety data and utilities (EQ-5D-3L) from the CheckMate-214 trial (NCT02231749). French costs for drug acquisition, drug administration, monitoring, terminal care, travel and adverse events were sourced from published prices. Treatment-specific utilities were calculated using the French value set. Costs and outcomes were discounted by 4.0% annually. Univariate deterministic and multivariate probabilistic sensitivity analyses (DSA, PSA) assessed robustness of the results. Outcomes of interest were total costs, quality-adjusted life-years (QALYs), life years (LYs), the incremental cost-utility ratio (ICUR), and the incremental cost-effectiveness ratio (ICER). Results NIVO+IPI was associated with higher total QALYs and LYs (3.53 and 4.95) versus sunitinib (2.71 and 3.87) and increased total cost (€160,751 versus €86,596), all respectively. This resulted in an ICUR of €89,793/QALY gained and an ICER of €68,626/LY gained versus sunitinib. Based on the DSA, key model drivers were drug acquisition costs, QALY discount rate, and variation of OS function parameters (95% confidence interval). The PSA confirmed robustness of the model results, with NIVO+IPI having a 62% probability of being cost-effective at a willingness-to-pay (WTP) threshold of €100,000/QALY. Conclusions Driven by an increased and sustained OS benefit, NIVO+IPI would be a cost-effective treatment when compared with sunitinib for 1L RCC patients in France at a WTP threshold of €100,000/QALY.

Date: 2019-11
References: Add references at CitEc
Citations:

Published in Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, 22, pp.S477. ⟨10.1016/j.jval.2019.09.410⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04875641

DOI: 10.1016/j.jval.2019.09.410

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().